Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Evaluation of xTAG Respiratory Viral Panel FAST and xTAG Human Parainfluenza Virus Analyte-Specific Reagents for detection of human parainfluenza viruses in respiratory specimens☆

Suresh B. Selvaraju, Rangaraj Selvarangan*

Department of Pathology and Laboratory Medicine, Children’s Mercy Hospitals and Clinics, Kansas City, MO 64108, USA

Department of Pediatrics, School of Medicine, University of Missouri, Kansas City, MO 64108, USA

Received 10 August 2011; accepted 14 November 2011

Abstract

The multiplex xTAG® Respiratory Viral Panel FAST (RVP FAST) research-use-only assay and xTAG® Human Parainfluenza Virus Analyte-Specific Reagent (HPIV-ASR) assay were evaluated with 99 culture-confirmed human parainfluenza virus (HPIV) – positive and – negative specimens and found to have analytical sensitivities of 95.2% and 100% and specificities of 98.3% and 96.6%, respectively. Since the in vitro diagnostic (IVD) version of the RVP FAST assay does not include HPIVs, the HPIV-ASR assay can be tested in parallel with RVP FAST-IVD for optimal detection of HPIVs.

© 2012 Elsevier Inc. All rights reserved.

Keywords: Respiratory viruses; Human parainfluenza viruses; xTAG RVP FAST; xTAG Human Parainfluenza Virus ASR; Analyte-specific reagents

1. Introduction

Nucleic acid–based assays have been developed for accurate and sensitive detection of respiratory viruses with a shorter turnaround time when compared to traditional methods (Gunson et al., 2005; Heim et al., 2003; Mahony, 2008; Pabbaraju et al., 2007). Most importantly, multiplex polymerase chain reaction (PCR) tests have recently been introduced to detect several respiratory virus types and subtypes that include newly identified viruses such as human metapneumovirus, coronaviruses, human bocavirus, 2009 H1N1 virus, etc., in addition to the respiratory viruses routinely isolated in a clinical laboratory (Arens et al., 2010; Balada-Llasat et al., 2011; Brunstein and Thomas, 2006; Gharabaghi et al., 2011; Lee et al., 2007; Mahony et al., 2007; Nolte et al., 2007; Rand et al., 2011; Scheltinga et al., 2005). One of the multiplex PCR-based assays, xTAG respiratory viral panel assay (RVP-v1), was the first assay cleared by the Food and Drug Administration for clinical testing of respiratory viruses. The performance characteristics of this assay have been reported and widely accepted for excellent detection of respiratory viruses in clinical specimens (Balada-Llasat et al., 2011; Gharabaghi et al., 2011; Krunic et al., 2007; Mahony et al., 2007; Pabbaraju et al., 2008; Rand et al., 2011). Recently, a second generation of this assay called xTAG RVP FAST (RVP FAST) with a faster assay time was approved for in vitro diagnostic (IVD) use in the USA. This IVD version detects 8 respiratory viruses but does not include human parainfluenza viruses (HPIVs). As an alternate approach, the manufacturer has developed a new xTAG HPIV Analyte-Specific Reagent (HPIV-ASR) to detect all human parainfluenza virus types. HPIV-ASR can be performed in parallel with RVP FAST assay in the same 96-well plate, with same nucleic acid extracts, and tested under the same assay and analysis conditions. Here we report the performance of the research-use-only version of the RVP FAST and the HPIV-ASR assays in detecting HPIVs in respiratory specimens.

A total of 99 respiratory specimens (HPIV positive = 41 and HPIV negative = 58) that were tested for HPIV by either virology culture (n = 89) or RVP-v1 testing (n = 10)

☆ This study was funded by a research grant from Luminex Corporation.

* Corresponding author. Tel.: +1-816-234-3031; fax: +1-816-234-1492.

E-mail address: rselvarangan@cmh.edu (R. Selvarangan).
were selected for this study. HPIV positives include 15 HPIV-1, 2 HPIV-2, and 24 HPIV-3. The specimens submitted for RVP-v1 testing were culture confirmed for inclusion into this study.

The sensitivity of the RVP FAST and HPIV-ASR assays was determined by using human parainfluenza reference strains obtained from American Type Culture Collection (ATCC). The initial viral titer (50% tissue culture infective dose [TCID₅₀]/0.2 mL) of HPIV reference strains was as follows: HPIV-1 = 1 × 10^{3.75} (ATCC no. VR-94); HPIV-2 = 1 × 10^{5.75} (ATCC no. VR-92); HPIV-3 = 1 × 10^{7.5} (ATCC no. VR-93), and HPIV-4 = 1 × 10^{3.5} (ATCC no. VR-1378). The HPIV strains were diluted 10-fold serially in universal transport medium and tested at different viral titer levels in triplicates as shown in Table 1.

Total nucleic acids were extracted with MS2 internal control (MS2 added per manufacturer’s instructions) using the NucliSENS easyMAG automated system (bioMérieux, Durham, NC, USA) and tested using RVP FAST assay (Luminex, Austin, TX, USA) according to the manufacturer’s instructions in a 96-well plate format.

The HPIV-ASR (Luminex) assay was performed with the same nucleic acid extracts used for RVP FAST testing in the same 96-well plate along with the RVP FAST assay. A 20-μL reaction volume containing xTAG RNase-free water (2.3 μL), xTAG 5× OneStep Buffer (4.0 μL), xTAG dNTP mix (1.1 μL), PIV primer (0.8 μL), MS2 primer (0.2 μL), xTAG OneStep enzyme mix (1.6 μL), and template nucleic acid (10 μL) was setup. The PCR was performed with the RVP FAST reaction conditions. The MagPlex-TAG magnetic beads (Luminex) for PIVs and MS2 internal control are supplied separately and are mixed before performing bead hybridization. Twenty microliters of bead mix per reaction was prepared by mixing 1 μL each of MagPlex-TAG-025 (HPIV) and MagPlex-TAG-055 (MS2) beads with 18 μL of 1x xTAG hybridization buffer. A 75-μL reporter solution per reaction was prepared with 1 μL of SA-PE G75 conjugate and 74 μL of 1x xTAG reporter buffer. Bead hybridization was performed with the RVP FAST reaction conditions. Following incubation, the plate was then read using the Luminex 100 xPONENT 3.1 system (Luminex) and the raw data was analyzed per RVP FAST protocol.

The limit of detection (LoD) analysis with HPIV reference strains is shown in Table 1. For the RVP FAST assay, the LoD was 10^0.00075 TCID₅₀/0.2 mL for HPIV-1, 10^0.075 for HPIV-2, 10^2.5 for HIPV-3, and 10^0.05 for HPIV-4. For the

Table 1
Limit of detection of xTAG RVP FAST and HPIV-ASR assays in detecting human parainfluenza viruses

| Viral target | Viral titer dilutions as 1× TCID₅₀/0.2 mL | RVP detection/typing | HPIV-ASR | Result |
|--------------|------------------------------------------|----------------------|----------|--------|
| HPIV-1       | 10₀.₇₅                                  | Detection (MFI)      | 16,549   | Positive |
|              | 10₀.₇₅                                  | Typing               | 16,275   | Positive |
|              | 10₀.₇₅                                  |                      | 100.075  | Positive |
|              | 10₀.₇₅                                  |                      | 100.0075 | Positive |
|              | 10₀.₇₅                                  |                      | 100.00075| Positive |
|              | 10₀.₇₅                                  |                      | 100.00075| Positive |
| HPIV-2       | 10₀.₉₅                                  | Detection (MFI)      | 17,310   | Positive |
|              | 10₀.₉₅                                  | Typing               | 17,336   | Positive |
|              | 10₀.₉₅                                  |                      | 100.075  | Positive |
|              | 10₀.₉₅                                  |                      | 100.0075 | Positive |
| HPIV-3       | 10₀.₇₅                                  | Detection (MFI)      | 16,471   | Positive |
|              | 10₀.₇₅                                  | Typing               | 16,400   | Positive |
|              | 10₀.₇₅                                  |                      | 100.5    | Negative |
|              | 10₀.₇₅                                  |                      | 100.05   | Negative |
| HPIV-4       | 10₀.₇₅                                  | Detection (MFI)      | 16,352   | Positive |
|              | 10₀.₇₅                                  | Typing               | 16,336   | Positive |
|              | 10₀.₇₅                                  |                      | 100.075  | Positive |

The limit of detection (LoD) is indicated in italic type. RVP FAST = xTAG Respiratory Viral Panel Fast assay; HPIV-ASR = xTAG Human Parainfluenza Virus Analyte-Specific Reagents; MFI = median fluorescence intensity.

The reference HPIV strains were serially diluted 10-fold using universal transport medium for viruses and tested in triplicates.

HPIV-ASR detects HPIV 1–4 subtypes but does not differentiate them.
Both specimens were negative by discrepant analysis with RVP-v1 and repeat HPIV-ASR assays. In each case, the HPIV-ASR assay was capable of detecting HPIVs through 1 additional dilution compared to the RVP FAST assay.

The study results showed comparable performance of both RVP FAST and HPIV-ASR versus the gold standard culture method in detecting HPIV in clinical specimens (Table 2). RVP FAST and HPIV-ASR showed overall analytical sensitivities of 95.2% and 100% and specificities of 98.3% and 96.6%, respectively. The RVP FAST assay failed to detect 1 HPIV-3 positive and incorrectly typed 1 HPIV-1 positive as HPIV-3. Both of these discrepant specimens were tested by RVP-v1 and repeat tested by RVP FAST. The RVP-v1 assay detected both specimens accurately. The repeat RVP FAST testing detected HPIV-1 correctly, but failed to detect the HPIV-3–positive specimen. The inability of the RVP FAST assay to detect this HPIV-3–positive specimen could be attributed to the low sensitivity of this assay as the median fluorescence intensity (MFI) on RVP FAST assay was 169 for HPIV-3 compared to RVP-v1 MFI of 2726 and HPIV-ASR MFI of 8644. Earlier reports also suggested lower sensitivity of 33.3% (Gadsby et al., 2010) and 42.8% (Gharabaghi et al., 2011) by RVP FAST assay in detecting HPIV-3 type. Overall, our study results demonstrated that the RVP FAST assay produced lower MFI for all HPIV-3 positives as compared to the HPIV-ASR assay with mean MFI difference of 3419.6. In contrast, Pabbaraju et al. (2011) reported a sensitivity of 100% for HPIV-3; such differences in detection rates may be explained by regional/geographical strain differences. Interestingly, the same report showed a lower sensitivity of 63.6% for HPIV-2 compared to 100% in our study. However, more HPIV-2–positive samples should be analyzed to draw definitive conclusions as only 2 positive specimens were analyzed in our study. HPIV-1 was detected at the same sensitivity level compared to 100% in our study. However, more HPIV-2–positive specimens were detected by the HPIV-ASR assay than RVP FAST. The inability of this assay to detect this HPIV-3–positive specimen could be attributed to the low sensitivity of this assay as the median fluorescence intensity (MFI) on RVP FAST assay was 169 for HPIV-3 compared to RVP-v1 MFI of 2726 and HPIV-ASR MFI of 8644. Earlier reports also suggested lower sensitivity of 33.3% (Gadsby et al., 2010) and 42.8% (Gharabaghi et al., 2011) by RVP FAST assay in detecting HPIV-3 type. Overall, our study results demonstrated that the RVP FAST assay produced lower MFI for all HPIV-3 positives as compared to the HPIV-ASR assay with mean MFI difference of 3419.6. In contrast, Pabbaraju et al. (2011) reported a sensitivity of 100% for HPIV-3; such differences in detection rates may be explained by regional/geographical strain differences. Interestingly, the same report showed a lower sensitivity of 63.6% for HPIV-2 compared to 100% in our study. However, more HPIV-2–positive samples should be analyzed to draw definitive conclusions as only 2 positive specimens were analyzed in our study. HPIV-1 was detected at the same sensitivity level of 93.3% as reported earlier (Pabbaraju et al., 2011).

The HPIV-ASR accurately detected all HPIV types (100%; n = 41/41); however, 2 culture-negative specimens were initially detected as HPIV positives which reduced the specificity of this assay to 96.6%. These 2 specimens were confirmed as “false-positive results” since discrepant analysis result using both RVP-v1 assay and repeat HPIV-ASR was negative.

In summary, the RVP FAST assay and the HPIV-ASR performed well in comparison to culture in detecting HPIVs with our clinical specimens. Earlier studies using the RVP FAST research-use-only version reported comparatively lower sensitivity of this assay in detecting HPIVs (Gadsby et al., 2010; Gharabaghi et al., 2011; Pabbaraju et al., 2011). However, these studies were conducted in other regional/geographical regions, and in this study we achieved slightly higher sensitivity using the HPIV-ASR assay. As HPIVs are not included in the US IVD RVP FAST assay, clinical laboratories may choose to include HPIV-ASR assay in parallel with the US IVD RVP FAST assay in the same 96-well plate. The reverse transcription–PCR amplification and bead hybridization for both RVP FAST and HPIV-ASR can be performed with the same nucleic acid extract under the same reaction conditions. Reading and analyzing the assay results can also be performed at the same time by creating a multi-batch with the xPONENT software. Since separate extraction of nucleic acid is not necessary, there will not be a considerable difference in total time except for setting up of the PCR assay and preparing bead hybridization reactions. We estimate a total time/hands-on time of 5.5 h/1.75 h (extraction = 90 min/40 min; multiplex RT-PCR = 155 min/35 min; hybridization and detection = 35 min/15 min; and reading and analysis = 30 min/5 min), to process a batch size of 24–48 specimens. When compared with the xTAG respiratory viral panel assay (RVP-v1), the use of the RVP FAST assay will result in cost savings due to a reduced hands-on time of approximately 2 h, in addition to an improved turnaround time as a result of the shorter protocol.

| Table 2 | Detection of human parainfluenza viruses by xTAG RVP FAST and HPIV-ASR assays in respiratory specimens |
|----------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|
| xTAG assays | Viral target Detected/culture confirmed | Percentage (95% confidence interval) | Sensitivity | Specificity | Positive predictive value | Negative predictive value |
| RVP FAST | Overall | 39/41 | 95.2% (82.6–99.2) | 98.3% (89.7–99.9) | 97.6% (85.6–99.9) | 96.7% (87.5–99.4) |
| | HPIV-1 | 14/15 | 93.3% (66–99.7) | 98.3% (89.7–99.9) | 93.3% (66–99.7) | 100% (92.3–100) |
| | HPIV-2 | 2/2 | 100% (97.7–100) | 100% (92.3–100) | 100% (91.7–100) | 100% (92.3–100) |
| | HPIV-3 | 23/24 | 95.8% (76.9–99.8) | 100% (92.3–100) | 100% (82.2–100) | 98.3% (89.7–99.9) |
| HPIV-ASR | Overall | 41/41 | 100% (89.3–100) | 96.6% (87.0–99.4) | 95.4% (82.9–99.2) | 100% (92–100) |
| | HPIV-1 | 15/15 | 100% (74.7–100) | 100% (92–100) | 100% (74.7–100) | 100% (92–100) |
| | HPIV-2 | 2/2 | 100% (91.8–100) | 100% (92–100) | 100% (91.8–100) | 100% (92–100) |
| | HPIV-3 | 24/24 | 100% (82.8–100) | 100% (92–100) | 100% (82.8–100) | 100% (92–100) |

The sensitivity and specificity of RVP FAST and HPIV-ASR assays were determined by comparing with culture as gold standard.

Both specimens were negative by discrepant analysis with RVP-v1 and repeat HPIV-ASR assays.

RVP FAST assay failed to detect 1 HPIV-3 culture positive.

RVP FAST assay typed 1 HPIV-1 type as HPIV-3 type initially. On discrepant analysis, RVP-v1 and RVP FAST assays typed this sample correctly as HPIV-1.

HPIV-ASR detected 2 culture-negative specimens as HPIV positives.
References

Arens MQ, Buller RS, Rankin A, Mason S, Whetsell A, Agapov E, Lee WM, Storch GA (2010) Comparison of the Eragen Multi-Code Respiratory Virus Panel with conventional viral testing and real-time multiplex PCR assays for detection of respiratory viruses. J Clin Microbiol 48:2387–2395.

Balada-Llasat JM, LaRue H, Kelly C, Rigali L, Pancholi P (2011) Evaluation of commercial ResPlex II v2.0, MultiCode-PLx, and xTAG respiratory viral panels for the diagnosis of respiratory viral infections in adults. J Clin Virol 50:42–45.

Brunstein J, Thomas E (2006) Direct screening of clinical specimens for multiple respiratory pathogens using the Genaco Respiratory Panels 1 and 2. Diagn Mol Pathol 15:169–173.

Gadsby NJ, Hardie A, Class ECJ, Templeton KE (2010) Comparison of the Luminex Respiratory Viral Panel Fast assay with in-house real-time PCR for respiratory viral infection diagnosis. J Clin Microbiol 48:2213–2216.

Gharabaghi F, Hawan A, Drews SJ, Richardson SE (2011) Evaluation of multiple commercial molecular and conventional diagnostic assays for the detection of respiratory viruses in children. Clin Microbiol Infect 17:1900–1906.

Gunson RN, Collins TC, Carman WF (2005) Real-time RT-PCR detection of 12 respiratory viral infections in four triplex reaction. J Clin Microbiol 33:341–344.

Heim A, Ebnet C, Harste G, Pring-Akerblom P (2003) Rapid and quantitative detection of human adenovirus DNA by real-time PCR. J Med Virol 70:2265–2274.

Krunic N, Yager TD, Himsworth D, Merante F, Yaghoubian S, Janeczko R (2007) xTAG RVP assay: analytical and clinical performance. J Clin Microbiol 45(S):S33–S46.

Lee WM, Grindle K, Pappas T, Marshall DJ, Moser MJ, Beaty EL, Shult PA, Prudent JR, Gern JE (2007) High-throughput, sensitive, and accurate multiplex PCR-microsphere flow cytometry system for large-scale comprehensive detection of respiratory viruses. J Clin Microbiol 45:2626–2634.

Mahony JB (2008) Detection of respiratory viruses by molecular methods. Clin Microbiol Rev 21:716–747.

Mahony JB, Chong S, Merante F, Yaghoubian S, Sinha T, Lisle C, Janeczko R (2007) Development of a respiratory virus panel test for detection of twenty human respiratory viruses by use of multiplex PCR and a fluid microbead-based assay. J Clin Microbiol 45:2965–2970.

Nolte FS, Marshall DJ, Rasbery C, Schievebelin S, Banks GG, Storch GA, Arens MQ, Buller RS, Prudent JR (2007) MultiCode-PLx system for multiplexed detection of seventeen respiratory viruses. J Clin Microbiol 45:2779–2786.

Pabbaraju J, Wong S, Tokaryk KL, Fonseca K, Drews SJ (2011) Comparison of the Luminex xTAG respiratory viral panel with xTAG respiratory viral panel fast for diagnosis of respiratory virus infections. J Clin Microbiol 49:1738–1744.

Pabbaraju K, Wong S, McMillan T, Lee BE, Fox JD (2007) Diagnosis and epidemiological studies of human metapneumovirus using real-time PCR. J Clin Microbiol 45:1900–1906.

Pabbaraju K, Tokaryk KL, Wong S, Fox JD (2008) Comparison of the Luminex xTAG respiratory viral panel with in-house nucleic acid amplification tests for diagnosis of respiratory virus infections. J Clin Microbiol 46:3056–3062.

Rand KH, Rampersaud H, Houch HJ (2011) A comparison of two multiplex methods for the detection of respiratory viruses: FilmArray RP and xTAG RVP. J Clin Microbiol 49:2449–2453.

Scheinting SA, Templeton KE, Beersma MF, Claas ECJ (2005) Diagnosis of human metapneumovirus and rhinovirus in patients with respiratory tract infections by an internally controlled multiplex real-time RNA PCR. J Clin Virol 33:306–311.